Psychedelics and cannabinoid neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of two new molecular conjugates for osteoarthritis and other pain indications, which mix CBD with Celecoxib, a generic drug commonly prescribed for osteoarthritis.
"CBD with celecoxib conjugation offers the opportunity for augmenting the treatment benefit by having potential superior efficacy and lower side effects, by administering lower amounts of the individual components of the conjugate," said to Benzinga Bob Dagher, Enveric's recently appointed chief medical officer.
